Status:

COMPLETED

68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis

Lead Sponsor:

Rigshospitalet, Denmark

Conditions:

Acute Myocardial Infarction

Eligibility:

All Genders

50+ years

Phase:

PHASE2

Brief Summary

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with myocardial infarction and investigate if it is a suitable tool for predicting myocardial reco...

Detailed Description

Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the ...

Eligibility Criteria

Inclusion

  • Age over 50 years
  • Acute myocardial infarction Group:
  • Verified first-time acute myocardial infarction treated with PCI
  • Control Group:
  • Previous healthy
  • No known cardiac disease

Exclusion

  • No prior history of acute coronary infarction
  • No prior history of Heart surgery
  • Not treated with anti-angiogenic medicine
  • Subject with pacemaker, cochlear implant or insulin pump
  • Pregnancy
  • Lactation
  • Severe claustrophobia
  • Severe obesity (weight above 140kg)
  • If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET\_tracer
  • If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial
  • If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨
  • Tupe I or II diabetes

Key Trial Info

Start Date :

February 20 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2020

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT03445884

Start Date

February 20 2018

End Date

July 1 2020

Last Update

July 14 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Physiology, Nuclear Medicine and PET

Copenhagen, Capital Region, Denmark, 2100